MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma

Proteasome inhibitors (PIs) are central to multiple myeloma (MM) therapy; however, resistance remains a major clinical challenge, particularly in relapsed/refractory disease. To identify functional mediators of carfilzomib (CFZ) resistance, we performed complementary gain-of-function CRISPR activati...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	María Labrador, Sara Cozzubbo, Mariangela Porro, Michela Cumerlato, Cecilia Bandini, Elisabetta Mereu, Tina Paradzik, Benedetta Donati, Veronica Manicardi, Domenica Ronchetti, Mattia D’Agostino, Alessandra Larocca, Francesca Gay, Benedetto Bruno, Alessia Ciarrocchi, Andrew Chatr-Aryamontri, Antonino Neri, Eugenio Morelli, Roberto Piva
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	MDPI AG 2026-05-01
Цуврал:	Cells
Нөхцлүүд:	MDM2 multiple myeloma proteasome inhibitors <i>TP53</i> drug resistance synthetic lethality
Онлайн хандалт:	https://www.mdpi.com/2073-4409/15/9/831
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!